

リウマチ・膠原病内科グループ 英語論文の業績 2017年

- 1) Naniwa T, Iwagaitsu S, Kajiura M. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission. *Mod Rheumatol.* 27(1): 29-34, 2017.
- 2) Iwagaitsu S, Naniwa T. Improvement of Arterial Wall Lesions in Parallel with Decrease of Plasma Pentraxin-3 Levels in a Patient with Refractory Takayasu Arteritis after Treatment with Tocilizumab. *Case Rep Rheumatol.* 2017: 4580967, 2017.
- 3) Iwai A, Naniwa T, Tamechika S, Maeda S. Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis. *Mod Rheumatol.* 27(3): 529-532, 2017.
- 4) Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada KE, Yuzawa Y, Amano K, Takasaki Y, Harigai M, Arimura Y, Makino H, Yasukawa M, Takemori N, Hasegawa H; Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan. <Collaborators> Murakawa Y, Muso E, Komatsuda A, Ito S, Fujii T, Kawakami A, Nakaya I, Saito T, Ito T, Hirawa N, Yamamura M, Nakano M, Nitta K, Ogura M, Naniwa T, Ozaki S, Hirahashi J, Ogawa N, Hosoya T, Wada T, Horikoshi S, Kawaguchi Y, Hayashi T, Yoshida M, Watanabe T, Inaguma D, Tsuruya K, Homma N, Takeuchi T, Nakagawa N, Takeda S, Katabuchi R, Iwano M, Atsumi T, Fujimoto S, Banno S, Sugihara T, Kobayashi M, Yamagata K, Homma S, Dobashi H, Tsuboi N, Ishizu A, Sugiyama H. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Res Ther.* 19(1): 218, 2017.